Suppr超能文献

严重急性呼吸综合征治疗的当前概念。

Current concepts in SARS treatment.

作者信息

Fujii Takeshi, Nakamura Tetsuya, Iwamoto Aikichi

机构信息

Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan.

出版信息

J Infect Chemother. 2004 Feb;10(1):1-7. doi: 10.1007/s10156-003-0296-9.

Abstract

The outbreak of severe acute respiratory syndrome (SARS) has drawn enormous attention and caused fear worldwide since early 2003. The disease appears to be under control now; however, the possible return of SARS must be emphasized. Although many clinical experiments have been reported, the treatment of SARS is largely anecdotal, and so far no treatment consensus has been reached. We summarize 14 clinical reports and attempt to assess the effectiveness of various treatment regimens. A combination treatment of steroids and ribavirin was widely used empirically from the outset of the epidemic. In general, the use of steroids for SARS seemed beneficial, but the optimal timing, dosage, and duration of treatment have not yet been determined. On the other hand, ribavirin administration apparently reduced neither the rate of intratracheal intubation nor that of mortality. Moreover, significant toxicity, such as hemolytic anemia, has been attributed to ribavirin. A few preliminary trials and in vitro data suggest the possibility of treating SARS with interferon. Other agents, including the HIV protease inhibitor glycyrrhizin and convalescent plasma, remain to be evaluated.

摘要

自2003年初以来,严重急性呼吸综合征(SARS)的爆发引起了全球的广泛关注并引发了恐慌。目前该疾病似乎已得到控制;然而,必须强调SARS可能会卷土重来。尽管已经报道了许多临床试验,但SARS的治疗很大程度上是基于个案经验,迄今为止尚未达成治疗共识。我们总结了14份临床报告,并试图评估各种治疗方案的有效性。从疫情开始,类固醇和利巴韦林的联合治疗就被经验性地广泛使用。总体而言,使用类固醇治疗SARS似乎有益,但治疗的最佳时机、剂量和持续时间尚未确定。另一方面,利巴韦林的使用显然既没有降低气管插管率,也没有降低死亡率。此外,利巴韦林还导致了诸如溶血性贫血等显著的毒性反应。一些初步试验和体外数据表明,使用干扰素治疗SARS具有可能性。其他药物,包括HIV蛋白酶抑制剂甘草甜素和康复期血浆,仍有待评估。

相似文献

1
Current concepts in SARS treatment.
J Infect Chemother. 2004 Feb;10(1):1-7. doi: 10.1007/s10156-003-0296-9.
3
Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada.
Clin Infect Dis. 2003 Oct 15;37(8):1139-42. doi: 10.1086/378304. Epub 2003 Sep 12.
4
6
Clinical trials and novel pathogens: lessons learned from SARS.
Emerg Infect Dis. 2004 Mar;10(3):389-94. doi: 10.3201/eid1003.030702.
7
Treatment of severe acute respiratory syndrome.
Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):583-91. doi: 10.1007/s10096-005-0004-z.
8
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.
Curr Opin Pulm Med. 2014 May;20(3):233-41. doi: 10.1097/MCP.0000000000000046.
10
[Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome].
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Jun;15(6):332-5.

引用本文的文献

1
Glycyrrhizin as a promising kryptonite against SARS-CoV-2: Clinical, experimental, and theoretical evidences.
J Mol Struct. 2023 Mar 5;1275:134642. doi: 10.1016/j.molstruc.2022.134642. Epub 2022 Nov 25.
2
Identification and Development of Therapeutics for COVID-19.
mSystems. 2021 Dec 21;6(6):e0023321. doi: 10.1128/mSystems.00233-21. Epub 2021 Nov 2.
3
SARS-CoV-2: Origin, Intermediate Host and Allergenicity Features and Hypotheses.
Healthcare (Basel). 2021 Aug 30;9(9):1132. doi: 10.3390/healthcare9091132.
4
COVID-19 versus SARS: A comparative review.
J Infect Public Health. 2021 Jul;14(7):967-977. doi: 10.1016/j.jiph.2021.04.007. Epub 2021 Apr 24.
6
Therapeutic Strategies in the Management of COVID-19.
Front Mol Biosci. 2021 Feb 4;7:636738. doi: 10.3389/fmolb.2020.636738. eCollection 2020.
8
Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.
Hum Vaccin Immunother. 2021 Jan 2;17(1):62-83. doi: 10.1080/21645515.2020.1797369. Epub 2020 Aug 12.
10
Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
Viruses. 2020 Jun 30;12(7):705. doi: 10.3390/v12070705.

本文引用的文献

3
WHO issues consensus document on the epidemiology of SARS.
Wkly Epidemiol Rec. 2003 Oct 24;78(43):373-5.
4
Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong.
Ann Intern Med. 2003 Nov 4;139(9):715-23. doi: 10.7326/0003-4819-139-9-200311040-00005.
6
Treatment of SARS with human interferons.
Lancet. 2003 Oct 4;362(9390):1159. doi: 10.1016/S0140-6736(03)14484-4.
7
Treatment of SARS with human interferons.
Lancet. 2003 Oct 4;362(9390):1158; author reply 1158-9. doi: 10.1016/S0140-6736(03)14482-0.
8
Early diagnosis of SARS coronavirus infection by real time RT-PCR.
J Clin Virol. 2003 Dec;28(3):233-8. doi: 10.1016/j.jcv.2003.08.004.
9
Severe acute respiratory syndrome: clinical outcome and prognostic correlates.
Emerg Infect Dis. 2003 Sep;9(9):1064-9. doi: 10.3201/eid0909.030362.
10
High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome.
Am J Respir Crit Care Med. 2003 Dec 15;168(12):1449-56. doi: 10.1164/rccm.200306-766OC. Epub 2003 Aug 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验